Over the past few days, medtech's biggest names gathered in San Francisco for the Transcatheter Cardiovascular Therapies (TCT ...

PLAINSBORO, N.J. (TNND) — Ozempic, which is the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat type 2 diabetes, was recently OK'd to also help reduce risks ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

Share on Pinterest Combining GLP-1 drugs like Ozempic with SGLT2 diabetes medications may help reduce the risk of heart attacks, stroke, and kidney disease, new research suggests. Alexandr Muşuc/Getty ...

Share on Pinterest Semaglutide drug use were linked to better kidney health in people with obesity and established heart disease in a new study. Image credit: Iuliia Burmistrova/Getty Images. Both ...

Valentine’s Day has come and gone, but it’s never too late to focus on your heart health. A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and ...

While drugs are available that reduce levels of lipoprotein (a), a protein associated with cardiovascular disease, no currently available therapies target this protein directly. Several companies are ...

Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...

Chronic kidney disease is a gradual, irreversible loss of kidney function caused by diabetes, hypertension, or ageing. It ...